STOCK TITAN

Opthea Limited - $OPT STOCK NEWS

Welcome to our dedicated page for Opthea news (Ticker: $OPT), a resource for investors and traders seeking the latest updates and insights on Opthea stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Opthea's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Opthea's position in the market.

Rhea-AI Summary
Opthea announces approval of nonproprietary drug name for lead biologic drug candidate
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
conferences
-
Rhea-AI Summary
Opthea Limited (NASDAQ:OPT; ASX:OPT) will highlight OPT-302, its first-in-class VEGF-C/D 'trap' inhibitor, at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting. Dr. Dante Pieramici will present new pharmacokinetics and safety data on OPT-302. Opthea will also participate in a wet Age-related Macular Degeneration (wet AMD) Key Opinion Leader (KOL) virtual fireside chat hosted by Oppenheimer & Co.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.57%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
Opthea Limited

Nasdaq:OPT

OPT Rankings

OPT Stock Data

296.61M
480.83M
9.46%
0.15%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Melbourne

About OPT

opthea limited (formerly circadian technologies) is a public australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. opthea's lead compound, opt-302, blocks two members of the vascular endothelial growth factor family, namely vegf-c and vegf-d, which cause blood vessels to grow and leak. aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet amd). opthea is currently investigating opt-302 in an ongoing phase 1/2a clinical trial in wet amd patients. enquiries can be directed to: info@opthea.com